Literature DB >> 16385563

Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma.

Andreas Bräuninger1, Roland Schmitz, Dörte Bechtel, Christoph Renné, Martin-Leo Hansmann, Ralf Küppers.   

Abstract

Hodgkin's and Reed/Sternberg (HRS) cells, the tumour cells in classical Hodgkin's lymphoma (HL), represent transformed B cells in nearly all cases. The detection of destructive somatic mutations in the rearranged immunoglobulin (Ig) genes of HRS cells in classical HL indicated that they originate from preapoptotic germinal centre (GC) B cells that lost the capacity to express a high-affinity B-cell receptor (BCR). Several aberrantly activated signalling pathways and transcription factors have been identified that contribute to the rescue of HRS cells from apoptosis. Among the deregulated signalling pathways, activation of multiple receptor tyrosine kinases in HRS cells appears to be a specific feature of HL. In about 40% of cases of classical HL the HRS cells are infected by Epstein-Barr virus (EBV), indicating an important role of EBV in HL pathogenesis. Interestingly, nearly all cases of HL with destructive Ig gene mutations eliminating BCR expression (e.g. nonsense mutations) are EBV-positive, suggesting that EBV-encoded genes have a particular function to prevent apoptosis of HRS-cell precursors that acquired such crippling mutations. This idea is further supported by the recent demonstration that isolated human GC B cells harbouring crippled Ig genes can be rescued by EBV from cell death, giving rise to lymphoblastoid cell lines. The molecular analysis of composite Hodgkin's and non-Hodgkin's lymphomas indicated that many cases develop from a common GC B-cell precursor in a multistep transformation process with both shared and distinct oncogenic events. Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16385563     DOI: 10.1002/ijc.21716

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  45 in total

1.  Soluble factors produced by activated CD4+ T cells modulate EBV latency.

Authors:  Noémi Nagy; Mónika Adori; Abu Rasul; Frank Heuts; Daniel Salamon; Dorina Ujvári; Harsha S Madapura; Benjamin Leveau; George Klein; Eva Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

2.  Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin's lymphoma.

Authors:  Christoph Renné; Jose Ignacio Martin-Subero; Maren Eickernjäger; Martin-Leo Hansmann; Ralf Küppers; Reiner Siebert; Andreas Bräuninger
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

3.  Role for HLA in susceptibility to infectious mononucleosis.

Authors:  Paul J Farrell
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

4.  Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival.

Authors:  Christoph Mancao; Wolfgang Hammerschmidt
Journal:  Blood       Date:  2007-08-06       Impact factor: 22.113

5.  Comparative analysis of oncogenic properties and nuclear factor-kappaB activity of latent membrane protein 1 natural variants from Hodgkin's lymphoma's Reed-Sternberg cells and normal B-lymphocytes.

Authors:  Nathalie Faumont; Aurélie Chanut; Alan Benard; Nadine Cogne; Georges Delsol; Jean Feuillard; Fabienne Meggetto
Journal:  Haematologica       Date:  2009-02-11       Impact factor: 9.941

6.  Clinical presentation, treatment, and outcomes among 65 patients with HIV-associated lymphoma treated at the University of North Carolina, 2000-2010.

Authors:  Satish Gopal; Kelly E Martin; Kristy L Richards; Joseph J Eron
Journal:  AIDS Res Hum Retroviruses       Date:  2011-12-01       Impact factor: 2.205

7.  Nutrients and genetic variation involved in one-carbon metabolism and Hodgkin lymphoma risk: a population-based case-control study.

Authors:  Julie L Kasperzyk; Ellen T Chang; Brenda M Birmann; Peter Kraft; Tongzhang Zheng; Nancy E Mueller
Journal:  Am J Epidemiol       Date:  2011-08-01       Impact factor: 4.897

8.  A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models.

Authors:  Wei Wei; Yuquan Lin; Zhihui Song; Wenming Xiao; Liqi Chen; Jiejing Yin; Yan Zhou; Stefan K Barta; Michael Petrus; Thomas A Waldmann; Yibin Yang
Journal:  Clin Cancer Res       Date:  2020-04-16       Impact factor: 12.531

Review 9.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

10.  Circulating clonotypic B cells in classic Hodgkin lymphoma.

Authors:  Richard J Jones; Christopher D Gocke; Yvette L Kasamon; Carole B Miller; Brandy Perkins; James P Barber; Milada S Vala; Jonathan M Gerber; Lan L Gellert; Mark Siedner; M Victor Lemas; Sarah Brennan; Richard F Ambinder; William Matsui
Journal:  Blood       Date:  2009-02-02       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.